IRIS
BONATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.130
AS - Asia 3.021
EU - Europa 1.954
SA - Sud America 295
AF - Africa 138
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.546
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.037
SG - Singapore 1.085
CN - Cina 1.001
VN - Vietnam 426
IT - Italia 322
IE - Irlanda 310
SE - Svezia 273
FI - Finlandia 257
DE - Germania 242
BR - Brasile 231
UA - Ucraina 216
HK - Hong Kong 203
TR - Turchia 109
NL - Olanda 96
ZA - Sudafrica 86
CA - Canada 73
FR - Francia 64
GB - Regno Unito 52
IN - India 39
JP - Giappone 38
RU - Federazione Russa 29
CI - Costa d'Avorio 27
BD - Bangladesh 25
AR - Argentina 24
AT - Austria 16
ES - Italia 16
BE - Belgio 15
IQ - Iraq 13
KR - Corea 13
EC - Ecuador 12
MX - Messico 11
PL - Polonia 9
CZ - Repubblica Ceca 8
ID - Indonesia 8
CL - Cile 7
LT - Lituania 7
MA - Marocco 7
PK - Pakistan 7
SA - Arabia Saudita 7
AU - Australia 6
VE - Venezuela 6
BO - Bolivia 4
CO - Colombia 4
DZ - Algeria 4
EE - Estonia 4
IR - Iran 4
JO - Giordania 4
KG - Kirghizistan 4
PH - Filippine 4
PT - Portogallo 4
PY - Paraguay 4
TW - Taiwan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BG - Bulgaria 3
KE - Kenya 3
RO - Romania 3
TN - Tunisia 3
AM - Armenia 2
CH - Svizzera 2
LV - Lettonia 2
LY - Libia 2
MN - Mongolia 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IL - Israele 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
MZ - Mozambico 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
SV - El Salvador 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.546
Salva come PNG Salva come JPEG
Città #
Singapore 536
Chandler 325
Jacksonville 322
Dublin 309
San Jose 298
Ashburn 267
Beijing 262
Santa Clara 255
Hong Kong 193
Dallas 137
Nanjing 116
Ho Chi Minh City 112
Ann Arbor 105
Hanoi 105
Boardman 102
Parma 98
Izmir 91
Dearborn 87
Johannesburg 84
San Mateo 71
Princeton 70
Lauterbourg 55
Los Angeles 52
Jinan 49
Toronto 49
Wilmington 47
Hebei 41
Munich 41
New York 40
Shenyang 40
Bologna 38
Hefei 36
Tokyo 36
Shanghai 32
Helsinki 31
Des Moines 30
Nanchang 30
Abidjan 27
Kunming 27
São Paulo 27
Moscow 26
Da Nang 23
Columbus 21
Changsha 19
Guangzhou 19
Düsseldorf 18
Haiphong 18
Woodbridge 17
Tianjin 16
Brussels 15
Council Bluffs 15
Milan 15
Montreal 14
Turku 14
Zhengzhou 14
Amsterdam 13
Nuremberg 13
Buffalo 12
Falls Church 12
London 12
Fremont 11
Grafing 11
Haikou 11
Chennai 10
Kocaeli 10
Orem 10
Rio de Janeiro 10
Seattle 10
Taizhou 10
The Dalles 10
Brooklyn 9
Hải Dương 9
Jiaxing 9
Lanzhou 9
Leawood 9
Pittsburgh 9
Vienna 9
Atlanta 8
Fuzhou 8
Houston 8
Seoul 8
Warsaw 8
Baghdad 7
Boston 7
Bremen 7
Chengdu 7
Denver 7
Hangzhou 7
Poplar 7
Redmond 7
Trezzano Sul Naviglio 7
Biên Hòa 6
Borås 6
Can Tho 6
Falkenstein 6
Frankfurt am Main 6
Modena 6
Porto Alegre 6
Taiyuan 6
Ankara 5
Totale 5.321
Salva come PNG Salva come JPEG
Nome #
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma 306
MEK1/2 KINASES DISABLE THE TUMOR SUPPRESSOR FUNCTIONS OF NATIVE BCR AND ABL1 KINASES TO IMPAIR ANTICANCER DRUGS’ RESPONSIVENESS IN TKI-RESISTANT PHILADELPHIA POSITIVE LEUKEMIAS 256
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH+-LEUKEMIA 240
Acenaphthenequinone thiosemicarbazone and its transition metal complexes: synthesis, structure, and biological activity. 167
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL 152
Elevated telomerase activity, minimal telomere loss in cord blood long-term cultures with extensive stem cell replication 151
Early proinflammatory activation of renal tubular cells by normal and pathologic IgG 145
MEK-INHIBITORS/ARSENIC TRIOXIDE COMBINATION THERAPY AS A NOVEL TREATMENT OPTION FOR TYROSINE KINASE INHIBITORS-RESISTANT PH plus -LEUKEMIA 138
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis. 137
Biochemical, Immunological, and Molecular Markers of Hemopoietic Precursor Cells. 136
Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis 135
Emerging MEK inhibitors 129
Treatment with Arsenic Trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells 128
Arsenic Trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 126
T cell receptor genes: a glance at normal and malignant hematopoiesis. 125
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent anti-tumor activity in vivo against human multiple myeloma xenograft model. 123
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts 122
MDM2 inhibition synergistically enhances cytotoxicity of MEK1 inhibitor and Arsenic Trioxide (ATO) in AML blasts that retain a functional p53 pathway 121
Emerging Raf inhibitors 121
Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization. 121
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 120
A micro-mechanically motivated model for the strength of heat-treated glass 120
Arsenic Trioxide in hematological malignancies: the new discovery of an ancient drug. 119
Discordant expression of terminal transferase and T cell receptor beta chain in fetal and pediatric thymocytes. 119
Terminal deoxynucleotidyl transferase (TdT) levels in hairy cell leukemia. 118
Ph1-positive acute myelocytic leukemia with high TdT levels. 118
BCL2 oncogene protein expression in human hematopoietic precursors during fetal life. 117
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. 116
p73 and p53 pathway in human breast cancers. 116
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 115
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia 114
Calibration of the Statistical-Interference Factors for the Design of Tempered Structural Glass 113
T-cell receptor beta-chain gene rearrangement and expression during human thymic ontogenesis. 113
Su di un caso di sclerodermia associato ad aplasia midollare globale. 113
Human T-cell receptor alpha chain gene during ontogeny 113
Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. 112
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts. 111
MEK-ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors 110
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. 109
Synthesis, characterisation, X-ray structure and biological activity of three new 5-formyluracil thiosemicarbazone complexes 107
Terminal deoxynucleotidyl transferase: a nuclear marker of hemopoietic precursors. Biochemical, immunological and clinical aspects. 105
Espressione degli antigeni CD1a, CD1b, CD1c in timo umano a diverse eta' dello sviluppo. 103
Expression of TCR beta chain gene N-diversity is not an early event in human thymic ontogeny 102
Synthesis, structure, spectroscopic properties and biological activity of mixed diorganotin(IV) complexes containing pyridine-2-carbaldehyde thiosemicarbazonato and diphenyldithiophosphinato ligands. 102
Hemopoiesis during human fetal life. Present knowledge and future prospects. 100
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4. 100
Synthesis, spectroscopic characterization and biological properties of new natural aldehydes thiosemicarbazones 99
La linfoadenopatia angio-immunoblastica: Osservazioni cliniche, patologiche ed immunologiche su di un caso. 98
MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia 96
Valutazione dell'attivita proliferativa delle cellule emopoietiche nelle sindromi preleucemiche. 96
Targeting the cancer initiating cell: the ultimate target for cancer therapy. 96
La mielofibrosi idiopatica asplenomegalica. Osservazioni cliniche e considerazioni su cinque casi. 94
Phenotype of the terminal transferase-positive cells in human foetal liver and bone-marrow: analysis with monoclonal antibodies. 94
Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. 93
The fine structure of HNK-1 (Leu7) positive cells. A study using an immunoperoxidase technique. 93
Phorbol ester-induced PKC{epsilon} down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. 93
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. 93
Terminal deoxynucleotidyl transferase-positive B cell precursors in fetal lymph nodes and extrahemopoietic tissues. 92
Terminal deoxynucleotidyl transferase in human fetal tissues. 92
Terminal deoxynucleotidyl transferase (TDT) expression correlates with the presence of N regions during human thymic ontogeny 92
TCR beta chain expression during human thymic development. 91
Philadelphia-positive chronic myelogenous leukemia with typical bcr/abl molecular features and atypical, prolonged survival. 90
The combination of MEK inhibitors and Arsenic Trioxide triggers in vitro and in vivo synergistic cytotoxicity in multiple myeloma through multiple signaling pathways 86
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 84
Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. 83
Selective Expression and Constitutive Phosphorylation of SHC Proteins in the CD34+ Fraction of Chronic Myelogenous Leukemias. 82
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. 81
Terminal deoxynucleotidyl transferase (TdT) in human foetuses. An immunofluorescent and biochemical study. 79
Leu-7-positive cells with monocyte phenotype show different ultrastructural features in comparison to Leu-7-positive cells with T-cell phenotype. 77
Medicina molecolare: nuovi strumenti per la conoscenza e la cura delle patologie dell'uomo. 76
Regulation of proliferation and cytokine expression of bone marrow fibroblasts: role of c-myb. 75
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways 74
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. 73
The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting. 72
Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model 48
Combined treatment with the MEK inhibitor PD0325901 and Arsenic Trioxide has potent antitumor activity in NOD-SCID mice bearing advanced tumors of human multiple myeloma. 44
THE COMBINATION OF MEK INHIBITORS AND ARSENIC TRIOXIDE TRIGGERS IN VITRO AND IN VIVO SYNERGISTIC CYTOTOXICITY IN MULTIPLE MYELOMA THROUGH MULTIPLE SIGNALING PATHWAYS 32
Arsenic Trioxide (ATO) Interacts Synergistically with MEK Inhibitors to Induce Apoptosis in STI571-Resistant Bcr-Abl Mutants 27
Totale 8.579
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.992
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.992
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021129 0 0 0 0 0 0 0 0 0 19 101 9
2021/2022380 5 10 0 14 12 16 63 72 20 34 18 116
2022/20231.154 138 121 92 86 102 121 5 67 372 14 28 8
2023/2024402 33 47 17 7 54 68 23 9 15 22 34 73
2024/20251.590 59 91 104 60 208 197 30 74 215 138 114 300
2025/20262.850 281 273 343 243 390 202 409 135 388 186 0 0
Totale 8.579